● Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Condition: Atrial Fibrillation (AF) · Sponsor: Anthos Therapeutics, Inc.

PhasePhase 3

Planned participants2500

Who can joinAll sexes, 65 Years to no upper limit

Healthy volunteersNo

About this study

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Anthos Therapeutics a Novartis Company · 1-888-669-6682 · novartis.email@novartis.com

Always discuss trial participation with your own doctor first.

Locations (789)

Anthos Investigative Site 1040	Birmingham, Alabama, United States	Recruiting
Anthos Investigational site 9939	Birmingham, Alabama, United States	Recruiting
Anthos Investigative Site 9947	Birmingham, Alabama, United States	Not Yet Recruiting
Anthos Investigative Site 1041	Mobile, Alabama, United States	Recruiting
Anthos Investigative Site 1089	Gilbert, Arizona, United States	Withdrawn
Anthos Investigative Site 1099	Peoria, Arizona, United States	Recruiting
Anthos Investigative Site 9906	Phoenix, Arizona, United States	Recruiting
Anthos Investigative Site 9927	Yuma, Arizona, United States	Recruiting
Anthos Investigative Site 9929	Huntington Beach, California, United States	Recruiting
Anthos Investigative Site 9959	Imperial, California, United States	Recruiting
Anthos Investigative Site 9921	Lancaster, California, United States	Recruiting
Anthos Investigative Site 1078	Loma Linda, California, United States	Recruiting

+ 777 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05712200